Selected article for: "median progression and survival time"

Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS
  • Document date: 2018_12_19
  • ID: r79h9yzz_513
    Snippet: Treatment for canine splenic haemangiosarcoma (HSA) includes surgery and adjuvant chemotherapy. Adjunctive metronomic chemotherapy (MC) has been shown to result in similar survivals when compared to anthracyclines (AC), whilst there are discordant results on the use of MC at the time of completion of AC‐based protocols. The aim of this study was to assess time to progression (TTP) and median survival time (MST) in dogs with stage I‐II splenic.....
    Document: Treatment for canine splenic haemangiosarcoma (HSA) includes surgery and adjuvant chemotherapy. Adjunctive metronomic chemotherapy (MC) has been shown to result in similar survivals when compared to anthracyclines (AC), whilst there are discordant results on the use of MC at the time of completion of AC‐based protocols. The aim of this study was to assess time to progression (TTP) and median survival time (MST) in dogs with stage I‐II splenic HSA and to compare different treatment protocols.

    Search related documents:
    Co phrase search for related documents
    • adjuvant chemotherapy and similar survival: 1
    • adjuvant chemotherapy and study aim: 1, 2, 3, 4, 5, 6
    • adjuvant chemotherapy and survival time: 1, 2, 3, 4, 5, 6
    • adjuvant chemotherapy and treatment protocol: 1, 2
    • adjuvant chemotherapy surgery and study aim: 1
    • different treatment protocol and treatment protocol: 1, 2, 3
    • discordant result and study aim: 1